BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
57 hedge funds and large institutions have $21.4M invested in BRAINSTORM CELL THERAPUTC in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 27 closing their positions.
0.53% less ownership
Funds ownership: 1.57% → 1.03% (-0.53%)
4% less call options, than puts
Call options by funds: $4.23M | Put options by funds: $4.43M
24% less funds holding
Funds holding: 75 → 57 (-18)
33% less capital invested
Capital invested by funds: $32.1M → $21.4M (-$10.7M)
50% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 24
67% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.32M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$496K |
| 3 |
E
Ergoteles
New York
|
+$443K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$378K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.27M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.53M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.01M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$889K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$759K |
BCLI Hedge Fund Activity: Q2 2021 in Review
57 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2021, worth a combined $21.4M — down 33% from $32.1M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of BCLI and 9 opened new positions — a net loss of 18 holders — while 24 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.32M. The largest seller was BlackRock, cutting an estimated $5.27M.
- 57 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2021, down from 75 in Q1 2021.
- Funds reported $21.4M of BRAINSTORM CELL THERAPUTC stock for Q2 2021, down 33% quarter-over-quarter.
- 9 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2021 and 27 closed out, a net change of -18 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2021 was Millennium Management, an estimated $1.32M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2021 was BlackRock, an estimated $5.27M sold.
Based on aggregated 13F filings for Q2 2021.